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Statins: what are they?
Statins are the most powerful cholesterol lowering drugs 
currently available. Statins inhibit 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG CoA) reductase, which leads 
to reduced cholesterol synthesis. In addition, low-density 
cholesterol receptors on the hepatocyte surface are 
upregulated, leading to increased clearance of cholesterol. 
The end result is a significant reduction in cholesterol levels, 
and a consequent significant reduction in mortality and 
cardiovascular events in the appropriate individual.
How effective are statins?
In a meta-analysis of 14 randomised controlled trials with 
>90 000 participants treated for 5 years:1 
• For every 1 mmol/L that low-density lipoprotein (LDL) 
cholesterol is reduced, mortality is reduced by 12% 
[95% CI: 9-16%] over five years, and one person’s life is 
saved for every 83 treated over five years [NNT 83].
• For every 1 mmol/L that LDL cholesterol is reduced, 
coronary heart disease is reduced by 19% [95% CI: 
15-24%] over five years. This translates into 14 [95% 
CI: 9-19] fewer deaths per 1 000 treated patients with 
pre-existing coronary heart disease over five years, 
compared to four [95% CI: 1-7] fewer deaths per 1 000 
treated patients without pre-existing coronary heart 
disease. 
The meta-analysis demonstrated a proximately linear 
relationship between absolute reductions in LDL cholesterol 
achieved and the proportional reductions in the incidence 
of coronary and other major vascular events. Larger LDL 
reductions produce larger reductions in vascular disease, 
e.g. a reduction in LDL cholesterol of 1.5 mmol/L may be 
expected to reduce the incidence of major vascular events 
by about one-third. 
The meta-analysis also demonstrated that the absolute 
benefit of statins increased with continuing treatment. On 
the other hand, one should bear in mind that the absolute 
benefit of treatment depends on the absolute risk of the 
patient being treated.
What are the lipid targets to aim for?
Currently, in normal people with a low-estimated global 
cardiovascular risk, an LDL cholesterol level below 3 mmol/L 
seems adequate. For high-risk individuals (i.e. risk factors 
are present), an LDL cholesterol level below 2.6 mmol/L 
should be the aim (primary prevention). For very high-risk 
individuals, such as in the case of secondary prevention, 
after an event, an LDL cholesterol level below 1.8 mmol/L 
should be the aim.2
In high-risk people who also have low HDL cholesterol and/
or elevated triglyceride levels, a statin should be prescribed 
and a fibrate or niacin (nicotinic acid) added. A triglyceride 
level greater than 1.7 mmol/L is abnormal, and an 
HDL cholesterol level below 1.02 mmol/L in men and 
1.29 mmol/L in women is considered by many as abnormal.
Is it dangerous to reduce LDL 
cholesterol?3
There are no intrinsic dangers to lowering LDL cholesterol, 
and no hard evidence to the contrary exists. Large 
randomised trials demonstrated a reduction in total mortality. 
There is no convincing evidence that cancer incidence will 
rise with statin use. There is some indication that statin use, 
per se, may increase the development of diabetes mellitus.
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Should we be initiating preventive 
measures earlier?3
Fatty streaks can already be demonstrated in adolescents 
and can be extensive by 30 years of age. We do treat high-
risk children, e.g. familial hypercholesterolemia. So this is a 
good question: Should we not start to treat people earlier if 
we want to change the natural history of atherosclerosis? 
There is some doubt as to whether statins or fibrates will 
reduce total mortality in primary prevention, i.e. in individuals 
without cardiovascular disease.
What about the elderly?
With increasing age, risk prediction tools, such as 
Framingham, become less accurate, clinical data are 
sparse, and decreasing life expectancy versus time to 
medication benefit shifts constantly. Yet, at least two pieces 
of evidence suggest that older age people, including these 
80 years and older, will also benefit from statins.4,5 In fact, 
the elderly may benefit by risk reduction in a short follow-up 
time after initiating treatment. 
This does not imply that a low-risk individual should be 
treated with a statin because of age alone.
Are there patient groups that may not 
benefit?
It seems that patients with heart failure may not benefit if 
statins are only then initiated. This does not imply that, in 
a high-risk individual that has been on a statin for a long 
period before developing heart failure, the statin now has to 
be stopped. There is also still some uncertainty if patients 
with chronic renal failure will benefit from statin therapy. 
More data are, however, necessary to determine the effects 
of statin therapy in other subgroups that may or may not 
benefit.
Can we stop atherosclerosis with 
statins?
Statin treatment diminishes the progression of coronary 
atherosclerosis, but regression has only been observed 
occasionally. Newer studies with intravascular ultrasound 
will probably clarify this issue in future. The ultimate 
expectation will be whether the process of atherosclerosis 
could undergo regression.
Conclusion 
Statin treatment benefits people when used as primary and, 
definitely, secondary prevention, by reducing cardiovascular 
events and mortality. The benefit varies with the baseline 
risk of the patient. 
This protective role of statins applies to many categories 
of patients and populations, including the elderly. Two real 
questions now dominate our thinking: How aggressive 
should we be with treatment, and how early should we start 
with treatment to get the maximum benefit in the long term? 
Safety concerns with the use of statins have mainly been 
addressed, and very few unfortunate individuals will 
experience serious side-effects. The side-effects that may 
accrue with life-long therapy must be established.
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